BIOMAT Database Logo BIOMAT Database Logo

Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer. 1976

D L Ahmann, and H F Bisel, and R T Eagan, and J H Edmonson, and R G Hahn, and M J O'Connell, and S Frytak

UI MeSH Term Description Entries
D011034 Podophyllotoxin A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives. Epipodophyllotoxin,CPH86,Condyline,Condylox,Podocon-25,Podofilm,Podofilox,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-Isomer,Wartec,Warticon
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000179 Acrylates Derivatives of acrylic acid (the structural formula CH2

Related Publications

D L Ahmann, and H F Bisel, and R T Eagan, and J H Edmonson, and R G Hahn, and M J O'Connell, and S Frytak
Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
February 1978, Gynecologic oncology,
D L Ahmann, and H F Bisel, and R T Eagan, and J H Edmonson, and R G Hahn, and M J O'Connell, and S Frytak
Phase II study of cytembena (NSC-104801) in advanced colorectal carcinoma.
January 1975, Cancer chemotherapy reports,
D L Ahmann, and H F Bisel, and R T Eagan, and J H Edmonson, and R G Hahn, and M J O'Connell, and S Frytak
Phase II evaluation of cytembena (NSC-104801) in patients with advanced ovarian carcinoma resistant to alkylating agents: brief communication.
December 1977, Journal of the National Cancer Institute,
D L Ahmann, and H F Bisel, and R T Eagan, and J H Edmonson, and R G Hahn, and M J O'Connell, and S Frytak
Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
January 1981, Cancer treatment reports,
D L Ahmann, and H F Bisel, and R T Eagan, and J H Edmonson, and R G Hahn, and M J O'Connell, and S Frytak
High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
January 1980, Cancer clinical trials,
D L Ahmann, and H F Bisel, and R T Eagan, and J H Edmonson, and R G Hahn, and M J O'Connell, and S Frytak
Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.
January 1975, Cancer chemotherapy reports,
D L Ahmann, and H F Bisel, and R T Eagan, and J H Edmonson, and R G Hahn, and M J O'Connell, and S Frytak
[Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer].
April 1981, Onkologie,
D L Ahmann, and H F Bisel, and R T Eagan, and J H Edmonson, and R G Hahn, and M J O'Connell, and S Frytak
Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide.
June 1987, European journal of cancer & clinical oncology,
D L Ahmann, and H F Bisel, and R T Eagan, and J H Edmonson, and R G Hahn, and M J O'Connell, and S Frytak
Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.
October 1985, Tumori,
D L Ahmann, and H F Bisel, and R T Eagan, and J H Edmonson, and R G Hahn, and M J O'Connell, and S Frytak
Phase II trial of VP-16-213 in advanced ovarian carcinoma.
October 1985, Gynecologic oncology,
Copied contents to your clipboard!